Literature DB >> 30533708

Draft Genome Sequence of the Xanthocidin-Producing Strain Streptomyces sp. AcE210, Isolated from a Root Nodule of Alnus glutinosa (L.).

Nico Ortlieb1,2,3, Nadine Keilhofer4, Silvia D Schrey4,5, Harald Gross2,6, Timo H J Niedermeyer1,2,3.   

Abstract

Streptomyces sp. strain AcE210 exhibited antibacterial activity toward Gram-positive microorganisms and turned out to be a rare producer of the specialized metabolite xanthocidin. The 10.6-Mb draft genome sequence gives insight into the complete specialized metabolite production capacity and builds the basis to find and locate the biosynthetic gene cluster of xanthocidin.

Entities:  

Year:  2018        PMID: 30533708      PMCID: PMC6256639          DOI: 10.1128/MRA.01190-18

Source DB:  PubMed          Journal:  Microbiol Resour Announc        ISSN: 2576-098X


ANNOUNCEMENT

As part of our ongoing efforts to investigate bioactive natural products from the Actinobacteria (1–9), we investigated the endophytic strain Streptomyces sp. AcE210. It exhibited antibacterial activity toward Gram-positive bacteria, and a chemical analysis revealed its ability to produce the natural product xanthocidin (10, 11). This compound belongs to the family of cyclopentenoid antitumor antibiotics that have been clinically applied in antitumor therapy (12). However, the fact that the original producing strain, Streptomyces xanthocidicus, lost the ability to biosynthesize xanthocidin (13) precluded biotechnological production and strain optimization as well as the conduct of biosynthetic and genetic studies. With strain AcE210 in hand, biosynthetic studies can now be revisited. To locate, analyze, and prove the biosynthetic gene cluster, the sequencing of this strain was initiated. Strain AcE210 was isolated from root nodules of Alnus glutinosa (L.) Gaertn. growing in Tübingen, Germany. After surface cleaning using sterile water, nodules were cracked open. Fragments were added to 50 ml of higher nitrogen content (HNC) medium (6% yeast extract, 0.05% SDS, 0.05% CaCl2 [pH 7.0]) and incubated at 42°C with shaking for 30 min. The suspension was filtered, and a dilution series was prepared. The filtered suspensions were plated onto International Streptomyces Project 2 (ISP-2) agar containing 5 g/liter cycloheximide, 2 g/liter nalidixic acid, and 5 g/liter nystatin. After 8 days at 27°C, strain AcE210 and eight other actinomycetes could be distinguished and separately isolated according to their morphological appearances. DNA of strain AcE210 was harvested from cultures grown for 3 days at 27°C in 100 ml of NL410 medium (1% dextrose, 1% glycerol, 0.5% oatmeal, 1% soy flour, 0.5% yeast extract, 0.5% Bacto Casamino Acids, and 0.01% CaCO3 in deionized water) under agitation (180 rpm) using a Qiagen Genomic-tip 100/G kit following the manufacturer’s protocol. Subsequently, a 10-kb SMRTbell library was generated from sheared genomic DNA (gDNA) using protocols and reagents according to the manufacturers’ instructions and was subjected to sequencing using a PacBio RS II sequencing platform. Sequencing reads were processed, filtered (PreAssembler filter v1), and mapped using SMRT Analysis v2.3.0, while de novo assembly was performed utilizing Falcon v0.2.1 (14) with the Falcon sense options multi output, 0.70 min idt, min cov 4, local match count threshold 2, max n read 200, and n core 6 and the overlap filtering settings max diff 240, max cov 360, min cov 5, and bestn 10. The length cutoff for seed reads was set at 6,000 bp for initial mapping as well as for preassembly. Quiver v1 was used for consensus polishing using the “only unambiguously mapped reads” option. Overall, 254,702 reads (N50, 6,342 bp; mean subread length, 5,265 bp) were assembled into a 10,567,477-nucleotide draft genome at 127-fold coverage. The resulting draft genome sequence consists of 4 contigs in total with a G+C content of 70.4%. The assembled contigs were annotated with the Prokaryotic Genome Annotation Pipeline (PGAP) (15), yielding a total of 8,873 predicted protein-coding sequences. The closest related type strains based on a multilocus sequence type (MLST) analysis are Streptomyces alboflavus NRRL B-2373 and Streptomyces avermitilis DSM 46492. Automated specialized metabolism analysis using AntiSMASH v4.0.2 (16) predicted 23 biosynthetic gene clusters. The biosynthetic genes involved in xanthocidin biosynthesis will be discussed in more detail elsewhere.

Data availability.

This whole-genome shotgun (WGS) project has been deposited in DDBJ/ENA/GenBank under the accession number QURC00000000. Raw sequencing data sets have been registered in the NCBI SRA database under the accession number SRP159767.
  14 in total

1.  Clinical experiences with sarkomycin in neoplastic diseases.

Authors:  J H BURCHENAL; C E CRANDALL; A GELLHORN; R B GOLBEY; D A KARNOFSKY; G B MAGILL; C P RHOADS; C C STOCK; S N YORUKOGLU
Journal:  Cancer Res       Date:  1956-11       Impact factor: 12.701

2.  Identification and activation of novel biosynthetic gene clusters by genome mining in the kirromycin producer Streptomyces collinus Tü 365.

Authors:  Dumitrita Iftime; Andreas Kulik; Thomas Härtner; Sabrina Rohrer; Timo Horst Johannes Niedermeyer; Evi Stegmann; Tilmann Weber; Wolfgang Wohlleben
Journal:  J Ind Microbiol Biotechnol       Date:  2015-10-03       Impact factor: 3.346

3.  Xanthocidin, a new antibiotic.

Authors:  K Asahi; J Nagatsu; S Suzuki
Journal:  J Antibiot (Tokyo)       Date:  1966-09       Impact factor: 2.649

4.  Identification of a novel aminopolycarboxylic acid siderophore gene cluster encoding the biosynthesis of ethylenediaminesuccinic acid hydroxyarginine (EDHA).

Authors:  Marius Spohn; Simone Edenhart; Mohammad Alanjary; Nadine Ziemert; Daniel Wibberg; Jörn Kalinowski; Timo H J Niedermeyer; Evi Stegmann; Wolfgang Wohlleben
Journal:  Metallomics       Date:  2018-05-23       Impact factor: 4.526

5.  The Immunosuppressant Brasilicardin: Determination of the Biosynthetic Gene Cluster in the Heterologous Host Amycolatopsis japonicum.

Authors:  Paul N Schwarz; Anina Buchmann; Luisa Roller; Andreas Kulik; Harald Gross; Wolfgang Wohlleben; Evi Stegmann
Journal:  Biotechnol J       Date:  2017-11-13       Impact factor: 4.677

6.  High-Quality Draft Genome Sequence of the Actinobacterium Nocardia terpenica IFM 0406, Producer of the Immunosuppressant Brasilicardins, Using Illumina and PacBio Technologies.

Authors:  Anina Buchmann; Michael Eitel; Pierre Koch; Paul N Schwarz; Evi Stegmann; Wolfgang Wohlleben; Marcin Wolański; Michał Krawiec; Jolanta Zakrzewska-Czerwińska; Carmen Méndez; Alma Botas; Luz Elena Núñez; Francisco Morís; Jesus Cortés; Harald Gross
Journal:  Genome Announc       Date:  2016-12-15

7.  antiSMASH 4.0-improvements in chemistry prediction and gene cluster boundary identification.

Authors:  Kai Blin; Thomas Wolf; Marc G Chevrette; Xiaowen Lu; Christopher J Schwalen; Satria A Kautsar; Hernando G Suarez Duran; Emmanuel L C de Los Santos; Hyun Uk Kim; Mariana Nave; Jeroen S Dickschat; Douglas A Mitchell; Ekaterina Shelest; Rainer Breitling; Eriko Takano; Sang Yup Lee; Tilmann Weber; Marnix H Medema
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

8.  Draft Genome Sequence of Streptomyces sp. Strain DH-12, a Soilborne Isolate from the Thar Desert with Broad-Spectrum Antibacterial Activity.

Authors:  Junjing Jiao; Julia Paterson; Tobias Busche; Christian Rückert; Jörn Kalinowski; Dharmesh Harwani; Harald Gross
Journal:  Genome Announc       Date:  2018-03-01

9.  Genome-based discovery of a novel membrane-bound 1,6-dihydroxyphenazine prenyltransferase from a marine actinomycete.

Authors:  Philipp Zeyhle; Judith S Bauer; Jörn Kalinowski; Kazuo Shin-ya; Harald Gross; Lutz Heide
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

10.  NCBI prokaryotic genome annotation pipeline.

Authors:  Tatiana Tatusova; Michael DiCuccio; Azat Badretdin; Vyacheslav Chetvernin; Eric P Nawrocki; Leonid Zaslavsky; Alexandre Lomsadze; Kim D Pruitt; Mark Borodovsky; James Ostell
Journal:  Nucleic Acids Res       Date:  2016-06-24       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.